T2 Biosystems to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the following upcoming investor conferences in New York City:

  • The NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 11:00 a.m. ET.
  • The Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016, at 2:50 p.m. ET.
  • CL King’s Best Ideas Conference on Tuesday, September 13, 2016 at 8:45 a.m. ET.

Live, listen-only webcasts of the presentations may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. Replays of the webcasts will be available shortly after the conclusion of the presentations and will be archived on the Company's website for 30 days.

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Media Contact: Susan Heins, Pure Communications susan@purecommunicationsinc.com 864-286-9597 Investor Contact: Matt Clawson, Pure Communications matt@purecommunicationsinc.com 949-370-8500

Source:T2 Biosystems, Inc.